To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post-treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow-up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (≥200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine ≥200 vs ≤30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (≥2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29-11.7) for sarcosine >200 vs <30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06-10.18), where (single) relapse-free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05-3.66). Urinary sarcosine may become a possible predictor for patients' outcomes, because patients with elevated post-treatment sarcosine could be predicted to have recurrent relapses of the disease.

Central European Institute of Technology Brno University of Technology Brno Czech Republic

Department of Chemistry and Biochemistry Mendel University in Brno Brno Czech Republic

Department of Pathological Physiology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Urology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Haas GP, Delongchamps N, Brawley OW, Wang CY, de La Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866‐3871. PubMed PMC

Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106‐130. PubMed

Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11(1):14‐23. PubMed PMC

Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910‐914. PubMed PMC

Khan AP, Rajendiran TM, Ateeq B, et al. The role of sarcosine metabolism in prostate cancer progression. Neoplasia. 2013;15(5):491‐501. PubMed PMC

Risk MC, Knudsen BS, Coleman I, et al. Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res. 2010;16(22):5414‐5423. PubMed PMC

Heger Z, Gumulec J, Cernei N, et al. Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non‐tumor and malignant prostatic cell lines. Prostate. 2016;76(7):679‐690. PubMed

Mottet N, Bellmunt J, Bolla M, et al. EAU‐ESTRO‐SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618‐629. PubMed

Lucarelli G, Fanelli M, Larocca AMV, et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0?ng/ml. Prostate. 2012;72(15):1611‐1621. PubMed

Couzin J. BIOMARKERS metabolite in urine may point to high‐risk prostate cancer. Science. 2009;323(5916):865. PubMed

Koutros S, Meyer TE, Fox SD, et al. Prospective evaluation of serum sarcosine and risk of prostate cancer in the prostate, lung, colorectal and ovarian cancer screening trial. Carcinogenesis. 2013;34(10):2281‐2285. PubMed PMC

Wu H, Liu TT, Ma CG, et al. GC/MS‐based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave‐assisted derivatization. Anal Bioanal Chem. 2011;401(2):635‐646. PubMed

Jentzmik F, Stephan C, Miller K, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol. 2010;58(1):12‐18. PubMed

Heger Z, Cernei N, Krizkova S, et al. Paramagnetic nanoparticles as a platform for FRET‐based sarcosine picomolar detection. Sci Rep. 2015;5:1‐7. PubMed PMC

Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. TrAC‐Trends Anal Chem. 2005;24(4):285‐294.

Meyer TE, Fox SD, Issaq HJ, et al. A reproducible and high‐throughput HPLC/MS method to separate sarcosine from α‐ and β‐alanine and to quantify sarcosine in human serum and urine. Anal Chem. 2011;83(14):5735‐5740. PubMed

Heger Z, Rodrigo MAM, Michalek P, et al. Sarcosine up‐regulates expression of genes involved in cell cycle progression of metastatic models of prostate cancer. PLoS ONE. 2016;11(11):1‐20. PubMed PMC